Nigel has been in the regulated financial services industry for nearly a decade, has previously owned a financial brokerage and has written many times for sites relating to personal finance and trading.
Alzamend Neuro, Inc (NASDAQ: ALZN) stock price saw a steep rise today off the back of a positive response from the FDA for the development of AL002, a cell-based therapeutic vaccine that aims to bolster the immune system in the face of Alzheimer’s disease.
Alzamend, a clinical-stage biopharmaceutical company, are specialists in the treatment of neurodegeneration and psychiatric disorders. Stock prices soared in mid-market trading today after a public announcement that the company received a written reply to its meeting request regarding the movement of AL002.
CEO of Alzamend Stephan Jackman is thoroughly pleased with the progress of the new Alzheimer’s treatment:
“We appreciate the thorough and meaningful response from the FDA, which provides us with the information and clarity needed to submit the IND application to initiate a clinical trial for AL002.”
“We appreciate the FDA’s recommendations, guidance and other helpful advice. We plan to augment our proposed clinical trial protocols and proceed accordingly.”
With clinical trials on the horizon, this is a promising time for Alzamend, it’s investors, and Alzheimers sufferers alike. Alzamend hopes to file the necessary IND by the end of November 2021, paving a clear route for clinical trials in the first quarter of 2022.
The progress of the cell-based therapeutic vaccine made an impressive impact on the market today, with gains reaching highs of 35% and the price currently teetering over the $3 level.
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .